Cite
MLA Citation
P. Langerbeins et al.. “IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL.” Hematological oncology, vol. 37, n.d., pp. 38–40. http://access.bl.uk/ark:/81055/vdc_100086210342.0x000050